Monopar Therapeutics stock faces insider selling after Q2 loss

Monopar Therapeutics stock (ISIN US61023L2079) was last at USD 78.200 on Nasdaq on October 6, 2026, down 0.12 percent from USD 78.290. The immediate company signal was a director transaction worth USD 659,386.

Director sale sets the latest signal

According to Investing.com on October 6, 2026, director Christopher M. Starr sold 8,400 common shares on October 1, 2026. The transactions used a Rule 10b5-1 plan, with weighted average sale prices of USD 78.09, USD 78.82 and USD 79.67.

The filing also showed an exercise of 8,400 options at USD 0.005 per share. After the transactions, Starr directly held 5,173 shares, making the filing a measurable ownership event rather than a change to Monopar's clinical pipeline.

Q2 loss beat the estimate

Monopar's investor-relations page identifies Q2 2026 as the quarter ended June 30, 2026, and describes the company as a clinical-stage biotechnology business developing radiopharmaceuticals and ALXN1840 for Wilson disease, according to Monopar Therapeutics.

For the quarterly release dated August 12, 2026, MarketBeat reported EPS of USD negative 0.62 against a consensus estimate of USD negative 0.64. The USD 0.02 improvement versus consensus is the clearest quantified operating comparison in the latest reported period, even as Monopar remains pre-commercial and revenue generation is not the central valuation driver.

Analyst target stays above the quote

The consensus picture remains constructive but carries a wide valuation gap. Investing.com lists a Strong Buy consensus from 12 analysts, with 11 Buy ratings, one Hold rating and zero Sell ratings.

The same consensus table gives an average 12-month target of USD 129.917, a low of USD 119 and a high of USD 145. The average target lies 66.13 percent above the USD 78.200 Nasdaq price, so the market is weighing development progress against the stock's distance from its 52-week high.

MNPR remains below its yearly high

Monopar's October 6 trading range was USD 75.560 to USD 78.200, with volume of 63,680 shares. The 52-week range was USD 50.070 to USD 124.820, while market capitalization stood at USD 512.3 million on the same date.

For investors, the key balance is visible in the numbers: Q2 EPS beat consensus by USD 0.02, but the stock remained 37.35 percent below its 52-week high. Clinical milestones and the development of ALXN1840 and MNPR-101 therefore remain central to the valuation case.

More news and analyses on Monopar Therapeutics stock